Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.

Malaria journal - 20 Mar 2018

Awandu Shehu S, Raman Jaishree, Makhanthisa Takalani I, Kruger Philip, Frean John, Bousema Teun, Niemand Jandeli, Birkholtz Lyn-Marie

Abstract excerpt

BACKGROUND: Primaquine (PQ) is recommended as an addition to standard malaria treatments in pre-elimination settings due to its pronounced activity against mature Plasmodium falciparum gametocytes, the parasite stage responsible for onward transmission to mosquitoes. However, PQ may trigger haemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. Additional human genetic factors, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Enzymologic

Share to Glucosephosphate Dehydrogenase

Share to Infant

Share to Malaria, Falciparum

Share to South Africa

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 29558929
DOI: 10.1186/s12936-018-2271-z
PMCID: PMC5859786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.PMID 29558929Read ↗

G6PD deficiency: global distribution, genetic variants and primaquine therapy.Semantic proximity Read ↗

Glucose-6-phosphate dehydrogenase deficiency and reduced haemoglobin levels in African children with severe malaria.Semantic proximity Read ↗

Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.Semantic proximity Read ↗

Genotypic glucose-6-phosphate dehydrogenase (G6PD) deficiency protects against Plasmodium falciparum infection in individuals living in Ghana.Semantic proximity Read ↗

Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.Semantic proximity Read ↗

Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug PrimaquineSemantic proximity Read ↗

Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern EthiopiaSemantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Low and heterogeneous prevalence of glucose-6-phosphate dehydrogenase deficiency in different settings in Ethiopia using phenotyping and genotyping approaches.Semantic proximity Read ↗

Prevalence and genetic variants of G6PD deficiency among malaria suspected patients in Shele and Lante Health Center, Southern EthiopiaSemantic proximity Read ↗

Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.Semantic proximity Read ↗

Prevalence of G6PD Deficiency and Distribution of Its Genetic Variants Among Malaria-Suspected Patients Visiting Metehara Health Center, Eastern EthiopiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.